In the United States (US), asthma is estimated to affect about 4 million children and 21 million adults, making it one of the most prevalent chronic diseases. Beyond high prevalence, asthma is a significant public health issue, one of the top thirty most disabling conditions globally. Patients with uncontrolled asthma are at risk for exacerbations, even if their disease is classified as mild or moderate. Recent data provide a better understanding of the role of inhaled corticosteroid (ICS) use concurrently with short-acting beta2-agnoists (SABAs), and primary care practitioners (PCPs) are key clinicians at the forefront of this paradigm shift. This webinar addresses clinical knowledge gaps that may prove to be barriers to improving outcomes in patients with uncontrolled mild or moderate asthma.